QiPing Feng, PhD

QiPing Feng, PhD is an Assistant Professor of Medicine in the Division of Clinical Pharmacology, Department of Medicine at Vanderbilt University Medical Center (VUMC). Dr. Feng completed her PhD training at Peking Union Medical College & Chinese Academy of Medical Science in China, and postdoctoral fellowship at the Mayo Clinic and VUMC. In 2012, she joined the faculty of the Division of Clinical Pharmacology at VUMC as a research instructor and was subsequently promoted to tenure track Assistant Professor in January 2017. Dr. Feng’s research focus is genetic analyses of lipid and lipid lowering drugs in the context of drug outcomes, pleiotropic effects, and related clinical phenotypes. She and her lab have 1) defined the genetics of statin response in BioVU (Clinical Pharmacology Therapeutics 2013, Pharmacogenomics J 2016); 2) elucidated the relationship between low LDL-C levels and clinical phenotypes (PLoS Med 2018, JAMA network OPEN 2019); and 3) defined the pleiotropic effects of statin drugs (JAMA network OPEN 2021). Dr. Feng received the Presidential Trainee Award and Jason Morrow Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT). She serves as an Associate Editor for BMC Pharmacology and Toxicology, and Frontiers in Cardiovascular Medicine and serves as an ad hoc reviewer for many journals. She participated in the selection committee for Vanderbilt Faculty Research Scholars and reviewed applications for the internal EDGE for Scholars program. She served as an expert on the Clinical Pharmacogenetics Implementation Consortium (CPIC) committee that defined guidelines for clinicians related to the pharmacogenetics of statin drugs. Dr. Feng is an active member of the Electronic Medical Records and Genomics (eMERGE) network. She is also a committee member for the pharmacogenomics community in ASCPT. She has been invited for both internal and external talks on her work, and she has published 70 papers, 65 of them research manuscripts.